Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Cellerai, Cristina ^a   Harari, Alexandre ^a,b   Stauss, Hans ^c   Yerly, Sabine ^d   Geretti, Anna Maria ^e   Carroll, Anne ^f   Yee, Thynn ^f   Ainsworth, Jonathan ^g   Williams, Ian ^h   Sweeney, John ⁱ   Freedman, Andrew ^j   Johnson, Margaret ^f   Pantaleo, Giuseppe ^a,b   Kinloch de Loes, Sabine ^c,f  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c University of Geneva Medical School ^*  (United Kingdom)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e Virology Department   (United Kingdom)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

^j CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GAMMA INTERFERON; INTERLEUKIN 2; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAG PROTEIN; HLA ANTIGEN CLASS 1;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; EARLY INTERVENTION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERM CARE; MALE; PROTEIN EXPRESSION; SEROCONVERSION; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SPECIES DIFFERENCE; TIME; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD4; ANTIGENS, CD8; COHORT STUDIES; EPITOPES; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION REGULATION; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PERFORIN; SPECIES SPECIFICITY; T-LYMPHOCYTES; TIME FACTORS; VIRUS REPLICATION;

EID: 79953681347     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018164     Document Type: Article

References (84)

1. Kovacs A, Connors M, (2004) HIV-1 and immune control: can we change the course of HIV-1? Lancet 363: 833-834.
2. Kaufmann GR, Zaunders JJ, Cunningham P, Kelleher AD, Grey P, et al. (2000) Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. Aids 14: 2643-2651.
3. Chun TW, Davey RT Jr, Engel D, Lane HC, Fauci AS, (1999) Re-emergence of HIV after stopping therapy. Nature 401: 874-875.
4. McMichael AJ, Rowland-Jones SL, (2001) Cellular immune responses to HIV. Nature 410: 980-987.
5. Pantaleo G, Koup RA, (2004) Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 10: 806-810.
6. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789.
7. Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, et al. (2006) Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev 211: 236-254.
8. Pantaleo G, Harari A, (2006) Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 6: 417-423.
9. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, et al. (2005) HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A 102: 7239-7244.
10. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204: 2473-2485.
11. Seder RA, Darrah PA, Roederer M, (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
12. Barry M, Bleackley RC, (2002) Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2: 401-409.
13. Berke G, (1995) The CTL's kiss of death. Cell 81: 9-12.
14. Russell JH, Ley TJ, (2002) Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20: 323-370.
15. Harari A, Enders FB, Cellerai C, Bart PA, Pantaleo G, (2009) Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure. J Virol 83: 2862-2871.
16. Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, et al. (2004) Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 200: 701-712.
17. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, et al. (2008) Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29: 1009-1021.
18. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, et al. (2002) HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3: 1061-1068.
19. Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE, et al. (2009) Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol 83: 11876-11889.
20. Horton H, Frank I, Baydo R, Jalbert E, Penn J, et al. (2006) Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J Immunol 177: 7406-7415.
21. Rehr M, Cahenzli J, Haas A, Price DA, Gostick E, et al. (2008) Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol 82: 3391-3404.
22. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, et al. (2010) Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 6: e1000917.
23. Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, et al. (2010) HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329: 174-180.
24. Deeks SG, Walker BD, (2007) Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27: 406-416.
25. Tilling R, Kinloch S, Goh LE, Cooper D, Perrin L, et al. (2002) Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. Aids 16: 589-596.
26. Tamura K, Dudley J, Nei M, Kumar S, (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
27. LAH-SRAW. Available:http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html.
28. Sanger F, Nicklen S, Coulson AR, (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 74: 5463-5467.
29. LANLW. Available: http://www.hiv.lanl.gov/content/immunology/tables/optimal_ctl_summary.html. Accessed 2010 May.
30. Kern F, Surel IP, Brock C, Freistedt B, Radtke H, et al. (1998) T-cell epitope mapping by flow cytometry. Nat Med 4: 975-978.
31. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, et al. (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260: 157-172.
32. Harari A, Cellerai C, Enders FB, Kostler J, Codarri L, et al. (2007) Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci U S A 104: 16233-16238.
33. Yerly S, Rutschmann OT, Opravil M, Marchal F, Hirschel B, et al. (1999) Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study. J Infect Dis 180: 850-853.
34. Carrington M, O'Brien SJ, (2003) The influence of HLA genotype on AIDS. Annu Rev Med 54: 535-551.
35. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004) Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432: 769-775.
36. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al. (2000) HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 97: 2709-2714.
37. Goulder PJ, Watkins DI, (2008) Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 8: 619-630.
38. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, et al. (2008) HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 105: 16725-16730.
39. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
40. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15: 893-900.
41. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
42. Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, et al. (2007) Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 195: 1762-1764.
43. Chun TW, Justement JS, Lempicki RA, Yang J, Dennis G Jr, et al. (2003) Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A 100: 1908-1913.
44. Lafeuillade A, Poggi C, Hittinger G, Counillon E, Emilie D, (2003) Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J Infect Dis 188: 1426-1432.
45. Yerly S, Gunthard HF, Fagard C, Joos B, Perneger TV, et al. (2004) Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. Aids 18: 1951-1953.
46. Guadalupe M, Sankaran S, George MD, Reay E, Verhoeven D, et al. (2006) Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 80: 8236-8247.
47. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, et al. (2005) Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 191: 1410-1418.
48. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, et al. (2008) Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 197: 126-133.
49. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, et al. (2003) Persistent immune activation in HIV-1 infection is associated with progression to AIDS. Aids 17: 1881-1888.
50. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, et al. (2007) HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 104: 6776-6781.
51. Tilton JC, Luskin MR, Johnson AJ, Manion M, Hallahan CW, et al. (2007) Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. J Virol 81: 2713-2725.
52. Harari A, Petitpierre S, Vallelian F, Pantaleo G, (2004) Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103: 966-972.
53. Gray CM, Lawrence J, Schapiro JM, Altman JD, Winters MA, et al. (1999) Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol 162: 1780-1788.
54. Guihot A, Tubiana R, Breton G, Marcelin AG, Samri A, et al. (2010) Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. Aids 24: 614-617.
55. Riviere Y, McChesney MB, Porrot F, Tanneau-Salvadori F, Sansonetti P, et al. (1995) Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 11: 903-907.
56. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13: 46-53.
57. Pereyra F, Heckerman D, Rothchild A, Brian B, Baker B, et al. (2008) Epitope Specific CD8+ T-Cell Responses Predict Spontaneous HIV Virus Replication. Oral abstract from AIDS VACCINE 2008 meeting.
58. Descours B, Avettand Fenoel V, Blanc C, Samri A, Mélard A, et al. (2010) Protective HLA alleles limit HIV reservoir in long term non progressors central memory CD4+ T cells. Oral abstract from IAS 2010 meeting.
59. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, et al. (2003) Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. Aids 17: 2581-2591.
60. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, et al. (2007) A whole-genome association study of major determinants for host control of HIV-1. Science 317: 944-947.
61. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, et al. (2009) HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol 83: 2743-2755.
62. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, et al. (2007) Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 81: 12382-12393.
63. Andersson J, Kinloch S, Sonnerborg A, Nilsson J, Fehniger TE, et al. (2002) Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection. J Infect Dis 185: 1355-1358.
64. Cellerai C, Perreau M, Rozot V, Enders FB, Pantaleo G, et al. (2010) Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression. J Virol 84: 3868-3878.
65. Iyasere C, Tilton JC, Johnson AJ, Younes S, Yassine-Diab B, et al. (2003) Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol 77: 10900-10909.
66. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, et al. (2003) HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 198: 1909-1922.
67. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, et al. (1994) Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369: 31-37.
68. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, et al. (2000) Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 192: 755-760.
69. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, et al. (2000) Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A 97: 3382-3387.
70. Koegl C, Wolf E, Hanhoff N, Jessen H, Schewe K, et al. (2009) Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res 14: 277-283.
71. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, et al. (2010) Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. Aids 24: 1598-1601.
72. Oxenius A, Price DA, Gunthard HF, Dawson SJ, Fagard C, et al. (2002) Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A 99: 13747-13752.
73. Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, et al. (2005) Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 192: 607-617.
74. Daucher M, Price DA, Brenchley JM, Lamoreaux L, Metcalf JA, et al. (2008) Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells. J Virol 82: 4102-4114.
75. Jansen CA, De Cuyper IM, Steingrover R, Jurriaans S, Sankatsing SU, et al. (2005) Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions. Aids 19: 1145-1154.
76. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, et al. (2001) Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A 98: 13288-13293.
77. Casazza JP, Betts MR, Picker LJ, Koup RA, (2001) Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol 75: 6508-6516.
78. Makedonas G, Betts MR, (2011) Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev 239: 109-124.
79. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, et al. (2008) Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 38: 350-363.
80. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
81. Nesbit L, Johnson SM, Pappagianis D, Ampel NM, (2010) Polyfunctional T lymphocytes are in the peripheral blood of donors naturally immune to coccidioidomycosis and are not induced by dendritic cells. Infect Immun 78: 309-315.
82. Makedonas G, Hutnick N, Haney D, Amick AC, Gardner J, et al. (2010) Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. PLoS Pathog 6: e1000798.
83. Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, et al. (2010) Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. Aids 24: 2803-2808.
84. Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, et al. (2007) Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis 45: 381-390.